This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2-amplified biliary tract cancer with an HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
Rimassa, Lorenza;
2025-01-01
Abstract
This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2-amplified biliary tract cancer with an HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
